secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vir Biotechnology, Inc. (VIR)
CIK:        0001706431
Form:       8-K
Filed at:   2022-04-07T23:59:59+00:00
Accession:  0001193125-22-098865
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vir Biotechnology appoints Johanna Friedl-Naderer as EVP and COO
----------------------------------------------------------------

- Appointed Johanna Friedl-Naderer, age 54, as EVP and COO effective April 4, 2022.
- She previously served as EVP and Chief Business Officer, Global since March 2022.
- Prior to Vir, spent 20+ years at Biogen, most recently as President of Europe, Canada & Partner Markets.
- Responsible for business development, finance, product development/regulatory, and corporate affairs.
- Compensation has not yet been determined; will be disclosed in a future amendment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1706431/000119312522098865/0001193125-22-098865-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1706431/000119312522098865/d254319d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-098865

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer